Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare 
Welcome,         Profile    Billing    Logout  
 12 Diseases   14 Trials   14 Trials   524 News 


«123456789»
  • ||||||||||  lamivudine / generics
    Characterization of Patient Pill Preferences from a Prospective Placebo vs. Placebo Ease of Swallowability Study () -  Aug 26, 2019 - Abstract #IDWeek2019IDWeek_2916;    
    When given free response, pills having a smooth coating was reinforced by 10 of the 25 (40%) participants who commented.Conclusion : Patient preferences for medications are varied and nuanced, but carry implications on patients self-reported likelihood to remain adherent to a regimen. Care should be taken in a clinical setting, such as HIV, to take pill characteristics into account when selecting antiretroviral regimens for patients.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Vitekta (elvitegravir) / Japan Tobacco, Gilead
    Journal:  Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection. (Pubmed Central) -  Aug 3, 2019   
    Bictegravir/emtricitabine/tenofovir AF is generally well tolerated, requires no prior HLA-B*5701 testing (making it more suitable for 'rapid start' treatment), fulfils the antiretroviral regimen requirement for patients with hepatitis B virus (HBV) co-infection (i.e. contains tenofovir AF and emtricitabine, both of which are active against HBV) and can be used in renally impaired patients with creatinine clearance (CR) ≥ 30 mL/min. Thus, although cost-effectiveness analyses would be beneficial, current data indicate that bictegravir/emtricitabine/tenofovir AF is a convenient initial and subsequent treatment option for adults with HIV-1 infection, including those co-infected with HBV, and provides the first non-pharmacologically boosted, INSTI-based, triple-combination STR suitable for patients with CR 30-50 mL/min.
  • ||||||||||  dolutegravir + abacavir sulphate +lamivudine / GSK, Epivir (lamivudine) / ViiV Healthcare, Ziagen (abacavir) / ViiV Healthcare
    Clinical, Journal:  Case report of Triumeq (abacavir/dolutegravir/lamivudine) associated rhabdomyolysis in a human immunodeficiency virus (HIV) infected patient. (Pubmed Central) -  May 29, 2019   
    Our data suggest an improvement in lipid profile and TG/HDL ratio in pretreated HIV-1-infected patients who switched to DTG/ABC/3TC over 48 weeks, especially in those previously receiving a bPI-based regimen. This case aims to recognize rhabdomyolysis as a rare, but possible adverse effect associated with the use of Triumeq for HIV-infected patients and therefore clinicians prescribing this combination should be aware of this potential side effect and counsel their patients accordingly.
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
    Trial completion date, Trial primary completion date, Adherence:  TAISTR: Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs (clinicaltrials.gov) -  Apr 26, 2019   
    P4,  N=50, Recruiting, 
    Trial completion date: Aug 2020 --> Aug 2021 Trial completion date: Mar 2019 --> Mar 2021 | Trial primary completion date: Dec 2018 --> Dec 2020
  • ||||||||||  Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead, Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
    New P4 trial:  DETOX Study Estudio DETOX (EUDRACT) -  Dec 4, 2018   
    P4,  N=110, Ongoing, 
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
    Trial termination, Monotherapy:  MONCAY: Study to Evaluate the Efficacy of MONotherapy of TiviCAY (clinicaltrials.gov) -  Nov 13, 2018   
    P3,  N=158, Terminated, 
    Trial completion date: Jul 2019 --> Jun 2020 Completed --> Terminated; 5 patients on tivicay had virological failure
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
    Enrollment open, Trial primary completion date, Adherence:  TAISTR: Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs (clinicaltrials.gov) -  Oct 18, 2018   
    P4,  N=50, Recruiting, 
    Completed --> Terminated; 5 patients on tivicay had virological failure Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2018 --> Dec 2018
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
    Trial completion, Monotherapy:  MONCAY: Study to Evaluate the Efficacy of MONotherapy of TiviCAY (clinicaltrials.gov) -  Sep 24, 2018   
    P3,  N=158, Completed, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2018 --> Dec 2018 Recruiting --> Completed
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
    Trial completion, Trial completion date, Trial initiation date:  SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over (clinicaltrials.gov) -  Feb 28, 2018   
    P4,  N=40, Completed, 
    Trial completion date: Jan 2019 --> Jul 2021 | Trial primary completion date: Jan 2018 --> Jul 2021 Active, not recruiting --> Completed | Trial completion date: Jul 2017 --> Jul 2017 | Initiation date: Jul 2015 --> Aug 2015
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Dovato (dolutegravir/lamivudine) / ViiV Healthcare
    New P1 trial:  To Assess the Relative Bioavailability (BA) of TRIUMEQ (clinicaltrials.gov) -  Feb 22, 2018   
    P1,  N=36, Not yet recruiting, 
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
    Trial primary completion date, Monotherapy:  MONCAY: Study to Evaluate the Efficacy of MONotherapy of TiviCAY (clinicaltrials.gov) -  Jan 17, 2018   
    P3,  N=160, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Jul 2017 --> Jul 2017 | Initiation date: Jul 2015 --> Aug 2015 Trial primary completion date: Jun 2018 --> Jun 2017
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
    Enrollment open, Enrollment change, Trial primary completion date:  Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019 (clinicaltrials.gov) -  Aug 10, 2017   
    P3,  N=80, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | N=40 --> 80 | Trial primary completion date: Apr 2019 --> Dec 2023